Contents
- (1) The Annex to Council Framework Decision 2004/757/JHA conta…
- (2) The Annex to Framework Decision 2004/757/JHA was added by…
- (3) Directive (EU) 2017/2103 repealed Decision 2005/387/JHA wi…
- (4) Therefore, due to the repeal of Decision 2005/387/JHA, the…
- (5) Ireland is bound by Directive (EU) 2017/2103 and is theref…
- (6) The United Kingdom is not bound by Directive (EU) 2017/210…
- (7) Denmark is not bound by Directive (EU) 2017/2103 and is th…
- (8) Framework Decision 2004/757/JHA should therefore be amende…
THE EUROPEAN COMMISSION,Having regard to the Treaty on the Functioning of the European Union,Having regard to Directive (EU) 2017/2103 of the European Parliament and of the Council of 15 November 2017 amending Council Framework Decision 2004/757/JHA in order to include new psychoactive substances in the definition of ‘drug’ and repealing Council Decision 2005/387/JHAnote, and in particular Article 3(3) thereof,Whereas:
(1)The Annex to Council Framework Decision 2004/757/JHAnote contains a list of substances which fall under the definition of drug under point 1(b) of Article 1 of that Framework Decision.
(2)The Annex to Framework Decision 2004/757/JHA was added by Directive (EU) 2017/2103. It lists all the new psychoactive substances, which were subjected to control measures and criminal penalties pursuant to Council Decision 2005/387/JHAnote before the adoption of Directive (EU) 2017/2103.
(3)Directive (EU) 2017/2103 repealed Decision 2005/387/JHA with effect from 23 November 2018. From the adoption of Directive (EU) 2017/2103 until 23 November 2018, five new psychoactive substances were subjected to control measures and criminal penalties under Decision 2005/387/JHA. However, those new psychoactive substances are not yet included into the Annex to Framework Decision 2004/757/JHA.
(4)Therefore, due to the repeal of Decision 2005/387/JHA, the following new psychoactive substances should be included in the Annex to Framework Decision 2004/757/JHA:
(a)N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) subjected to control measures by Council Implementing Decision (EU) 2017/2170note;
(b)N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) subjected to control measures by Council Implementing Decision (EU) 2018/747note;
(c)1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) subjected to control measures by Council Implementing Decision (EU) 2018/748note;
(d)N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) and 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) subjected to control measures by Council Implementing Decision (EU) 2018/1463note.
(5)Ireland is bound by Directive (EU) 2017/2103 and is therefore taking part in the adoption and application of this delegated directive.
(6)The United Kingdom is not bound by Directive (EU) 2017/2103 and is therefore not taking part in the adoption and application of this delegated directive and is not bound by it or subject to its application.
(7)Denmark is not bound by Directive (EU) 2017/2103 and is therefore not taking part in the adoption and application of this delegated directive and is not bound by it or subject to its application.
(8)Framework Decision 2004/757/JHA should therefore be amended accordingly,
HAS ADOPTED THIS DIRECTIVE:
Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.